MX368484B - Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. - Google Patents

Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.

Info

Publication number
MX368484B
MX368484B MX2014007183A MX2014007183A MX368484B MX 368484 B MX368484 B MX 368484B MX 2014007183 A MX2014007183 A MX 2014007183A MX 2014007183 A MX2014007183 A MX 2014007183A MX 368484 B MX368484 B MX 368484B
Authority
MX
Mexico
Prior art keywords
immune response
response against
humoral immune
vaccination
producing
Prior art date
Application number
MX2014007183A
Other languages
English (en)
Other versions
MX2014007183A (es
Inventor
Breunig Karin
Behrens Sven-Erik
Original Assignee
Martin Luther Univ Halle Wittenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47681476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX368484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martin Luther Univ Halle Wittenberg filed Critical Martin Luther Univ Halle Wittenberg
Publication of MX2014007183A publication Critical patent/MX2014007183A/es
Publication of MX368484B publication Critical patent/MX368484B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La presente invención se refiere a las levaduras recombinantes de la especie Kluyveromyces lactis para la producción de una inmunorespuesta humoral contra los antígenos definidos, con la producción de dichas levaduras, y con el uso de las mismas para la vacunación protectora contra los patógenos y las células malignas que contienen dichos antígenos.
MX2014007183A 2011-12-13 2012-12-12 Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos. MX368484B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011121069A DE102011121069A1 (de) 2011-12-13 2011-12-13 Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
PCT/DE2012/001205 WO2013107436A1 (de) 2011-12-13 2012-12-12 Vakzinierung mittels rekombinanter hefe durch erzeugung einer protektiven humoralen immunantwort gegen definierte antigene

Publications (2)

Publication Number Publication Date
MX2014007183A MX2014007183A (es) 2014-11-25
MX368484B true MX368484B (es) 2019-10-04

Family

ID=47681476

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007183A MX368484B (es) 2011-12-13 2012-12-12 Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.

Country Status (15)

Country Link
US (1) US11065312B2 (es)
EP (1) EP2844759B1 (es)
JP (1) JP6313215B2 (es)
KR (1) KR102027400B1 (es)
CN (1) CN104428417B (es)
BR (1) BR112014014390B1 (es)
CA (1) CA2859231C (es)
DE (2) DE102011121069A1 (es)
DK (1) DK2844759T3 (es)
ES (1) ES2690792T3 (es)
MX (1) MX368484B (es)
PL (1) PL2844759T3 (es)
RU (1) RU2630620C2 (es)
WO (1) WO2013107436A1 (es)
ZA (1) ZA201405034B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
JP7372647B2 (ja) * 2019-06-27 2023-11-01 国立研究開発法人農業・食品産業技術総合研究機構 α‐リノレン酸産生能が向上した酵母またはその培養物
CN110646614B (zh) * 2019-07-15 2023-05-23 新乡学院 Ibdv抗体的elisa试剂盒和测试方法、有效抗体效价确定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015140A1 (en) * 1989-05-30 1990-12-13 Commonwealth Scientific And Industrial Research Organisation Production of ibdv vp2 in highly immunogenic form
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US6234977B1 (en) 2000-01-28 2001-05-22 Michael Christy Variable-force monofilament sensory device and methods of using same
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
EP1908822B1 (en) * 2003-03-24 2010-10-13 Intervet International B.V. Infectious bursal disease virus mutants and vaccines
ES2242542B1 (es) * 2004-04-30 2006-12-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la produccion en levaduras de capsidas virales vacias compuestas por proteinas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
JP2008508320A (ja) * 2004-07-29 2008-03-21 カイロン コーポレイション Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
AU2005295317B2 (en) 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN101405026B (zh) 2006-02-02 2015-04-22 全球免疫股份有限公司 用于诱导免疫应答的基于酵母的疫苗
WO2008153339A2 (en) * 2007-06-12 2008-12-18 Univ Sungkyunkwan Found A vaccine for treating or preventing pasteurellosis using a yeast surface-expression system
DE102008057451A1 (de) * 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
CN101638824B (zh) 2009-03-16 2012-08-08 浙江双友物流器械股份有限公司 一种耐磨织带
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses

Also Published As

Publication number Publication date
RU2014127435A (ru) 2016-02-10
DK2844759T3 (en) 2018-11-05
KR102027400B1 (ko) 2019-10-04
US20150190486A1 (en) 2015-07-09
US11065312B2 (en) 2021-07-20
BR112014014390B1 (pt) 2022-08-09
WO2013107436A1 (de) 2013-07-25
ES2690792T3 (es) 2018-11-22
CA2859231C (en) 2019-04-30
CA2859231A1 (en) 2013-07-25
DE112012005213A5 (de) 2014-11-13
BR112014014390A2 (pt) 2020-12-08
KR20140105821A (ko) 2014-09-02
EP2844759A1 (de) 2015-03-11
ZA201405034B (en) 2015-12-23
CN104428417A (zh) 2015-03-18
WO2013107436A8 (de) 2015-01-15
MX2014007183A (es) 2014-11-25
DE102011121069A1 (de) 2013-06-13
CN104428417B (zh) 2020-05-05
JP2015507472A (ja) 2015-03-12
RU2630620C2 (ru) 2017-09-11
JP6313215B2 (ja) 2018-04-18
PL2844759T3 (pl) 2019-01-31
EP2844759B1 (de) 2018-07-18

Similar Documents

Publication Publication Date Title
PH12017500727A1 (en) Modified virus-like particles of cmv
MX2018002705A (es) Cepas de levadura para la expresion y secrecion de proteinas heterologas a altas temperaturas.
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
MX2019004568A (es) Produccion mejorada de derivados de acidos grasos.
IN2014CN02136A (es)
WO2013054199A3 (en) Cmv antigens and uses thereof
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
MX350096B (es) Preservación asistida con vacío de productos biológicos, en particular de vacunas.
MX368484B (es) Levadura recombinante para usarse para producir una respuesta inmune humoral protectora contra antígenos definidos.
WO2012142302A3 (en) Biocatalytic process for preparing eslicarbazepine and analogs thereof
SG10201808644PA (en) Recombinant mycobacterium as a vaccine
WO2012112416A3 (en) Method of producing n-butyraldehyde
WO2013019603A3 (en) Linear expression cassettes and uses thereof
IN2014CN02963A (es)
PT2725098T (pt) Estirpe de levedura kluyveromyces lactis e métodos para a produção de açúcares, etanol, beta-galactosidase e biomassa
EP2678440A4 (en) HEFESTAMM FOR THE PREPARATION OF PROTEINS WITH MODIFIED O-GLYCOSYLATION
EA028913B9 (ru) Получение антител высокой чистоты в pichia pastoris
WO2013160335A3 (en) Antigens and antigen combinations
EP2925879A4 (en) IMPROVED CULTURE MEDIA AND PROCESS FOR PRODUCING PROTEIN ENHANCED BY PICHIA STRAINS
WO2013173256A3 (en) New and improved influenza vaccines
RU2011115880A (ru) Способ получения селенсодержащего препарата биомассы laetiporus sulphureus mz-22
WO2013093514A3 (en) Vaccines - peptides
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Legal Events

Date Code Title Description
FG Grant or registration